By John Harbison|2017-10-30T16:40:47-08:00October 30, 2017|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th
